JY
CNTB

Jeff Yass’s Connect Biopharma Holdings CNTB Stock Holding History

Jeff Yass’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,900
Closed -$39K – 13516
2026
Q1 		$39K Buy
+14,900
New +$38.8K ﹤0.01% 12696

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Jeff Yass's CNTB Position: Q2 2026 in Review

Jeff Yass reduced its Connect Biopharma Holdings (CNTB) stake by 63% in Q2 2026, selling an estimated $428K and leaving 102,148 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #11530.

Jeff Yass first reported a position in CNTB in Q4 2021 and has held it in 9 quarters since. The position peaked at $730K in Q1 2026. 56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • Jeff Yass held 102,148 shares of Connect Biopharma Holdings worth $243K as of Q2 2026.
  • Jeff Yass sold 176,660 Connect Biopharma Holdings shares in Q2 2026, an estimated $428K.
  • Connect Biopharma Holdings made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11530 holding.
  • Jeff Yass first reported a position in Connect Biopharma Holdings in Q4 2021 and has held it in 9 quarters since.
  • Jeff Yass's Connect Biopharma Holdings position peaked at $730K in Q1 2026.
  • 56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.